Roche may have to pony up more for Genentech if Avastin does well

NEW YORK Genentech’s price tag for Roche Holding may get more expensive, depending on test results for a cancer drug the companies jointly market, according to Bloomberg.

The Basel, Switzerland-based company might have to increase its offer for South San Francisco, Calif.-based Genentech if test results show Avastin working against a larger number of tumors.

If tests are successful, Avastin (bevacizumab) may become a first-choice drug for treating colon tumors. According to Bloomberg.

Roche recently offered $89 per share for the remaining 44 percent of Genentech that it doesn’t already own.